Celldex Therapeutics Stock Buy Hold or Sell Recommendation
| CLDX Stock | USD 20.42 0.28 1.39% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Celldex Therapeutics is 'Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Celldex Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Celldex Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Celldex Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide. In addition, we conduct extensive research on individual companies such as Celldex and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Celldex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Celldex |
Execute Celldex Therapeutics Buy or Sell Advice
The Celldex recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Celldex Therapeutics. Macroaxis does not own or have any residual interests in Celldex Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Celldex Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Celldex Therapeutics Trading Alerts and Improvement Suggestions
| Celldex Therapeutics generated a negative expected return over the last 90 days | |
| Celldex Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 7.02 M. Net Loss for the year was (157.86 M) with loss before overhead, payroll, taxes, and interest of (156.53 M). | |
| Celldex Therapeutics currently holds about 356.82 M in cash with (157.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.63. | |
| Latest headline from gurufocus.com: Celldex Therapeutics Inc Announces Participation in Upcoming Healthcare Conferences |
Celldex Therapeutics Returns Distribution Density
The distribution of Celldex Therapeutics' historical returns is an attempt to chart the uncertainty of Celldex Therapeutics' future price movements. The chart of the probability distribution of Celldex Therapeutics daily returns describes the distribution of returns around its average expected value. We use Celldex Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Celldex Therapeutics returns is essential to provide solid investment advice for Celldex Therapeutics.
| Mean Return | -0.34 | Value At Risk | -5.37 | Potential Upside | 3.96 | Standard Deviation | 3.04 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Celldex Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Celldex Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Celldex Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Celldex Therapeutics back and forth among themselves.
| Shares | Woodline Partners Lp | 2024-12-31 | 2 M | T. Rowe Price Investment Management,inc. | 2024-12-31 | 1.7 M | Polar Capital Holdings Plc | 2024-12-31 | 1.6 M | Deep Track Capital, Lp | 2024-12-31 | 1.5 M | Geode Capital Management, Llc | 2024-12-31 | 1.5 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.3 M | Rock Springs Capital Management Lp | 2024-12-31 | 1.2 M | Goldman Sachs Group Inc | 2024-12-31 | 1.2 M | Pictet Asset Manangement Sa | 2024-12-31 | 1.1 M | Wellington Management Company Llp | 2024-12-31 | 9 M | Blackrock Inc | 2024-12-31 | 5.5 M |
Celldex Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 32.6M | (4.7M) | (9.7M) | 5.4M | (6.5M) | (6.1M) | |
| Free Cash Flow | (42.0M) | (62.2M) | (105.6M) | (109.1M) | (157.8M) | (149.9M) | |
| Depreciation | 3.9M | 3.1M | 2.9M | 3.0M | (12.6M) | (11.9M) | |
| Other Non Cash Items | 13.0M | (1.1M) | (5.8M) | (6.2M) | 16K | 15.2K | |
| Capital Expenditures | 1.6M | 1.2M | 1.8M | 1.8M | 1.9M | 1.5M | |
| Net Income | (59.8M) | (70.5M) | (112.3M) | (141.4M) | (157.9M) | (150.0M) | |
| End Period Cash Flow | 43.8M | 39.1M | 29.4M | 34.8M | 28.4M | 32.4M | |
| Investments | (98.2M) | (214.9M) | 89.9M | (105.8M) | (290.1M) | (275.6M) | |
| Change Receivables | (777K) | 2.3M | (787K) | 1.6M | 1.8M | 1.9M | |
| Change To Netincome | 5.1M | 15.7M | 7.6M | 9.6M | 11.0M | 15.7M |
Celldex Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Celldex Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Celldex Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Celldex stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.2 | |
β | Beta against Dow Jones | 1.07 | |
σ | Overall volatility | 3.08 | |
Ir | Information ratio | -0.07 |
Celldex Therapeutics Volatility Alert
Celldex Therapeutics exhibits very low volatility with skewness of -0.22 and kurtosis of -0.51. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Celldex Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Celldex Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Celldex Therapeutics Fundamentals Vs Peers
Comparing Celldex Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Celldex Therapeutics' direct or indirect competition across all of the common fundamentals between Celldex Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Celldex Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Celldex Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Celldex Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Celldex Therapeutics to competition |
| Fundamentals | Celldex Therapeutics | Peer Average |
| Return On Equity | -0.27 | -0.31 |
| Return On Asset | -0.19 | -0.14 |
| Operating Margin | (47.68) % | (5.51) % |
| Current Valuation | 683.88 M | 16.62 B |
| Shares Outstanding | 66.38 M | 571.82 M |
| Shares Owned By Institutions | 100.00 % | 39.21 % |
| Number Of Shares Shorted | 9.19 M | 4.71 M |
| Price To Earning | (2.21) X | 28.72 X |
| Price To Book | 1.88 X | 9.51 X |
| Price To Sales | 190.45 X | 11.42 X |
| Revenue | 7.02 M | 9.43 B |
| Gross Profit | (156.53 M) | 27.38 B |
| EBITDA | (191.9 M) | 3.9 B |
| Net Income | (157.86 M) | 570.98 M |
| Cash And Equivalents | 356.82 M | 2.7 B |
| Cash Per Share | 7.63 X | 5.01 X |
| Total Debt | 3.81 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 12.29 X | 2.16 X |
| Book Value Per Share | 11.25 X | 1.93 K |
| Cash Flow From Operations | (157.78 M) | 971.22 M |
| Short Ratio | 11.53 X | 4.00 X |
| Earnings Per Share | (2.45) X | 3.12 X |
| Target Price | 63.55 | |
| Number Of Employees | 186 | 18.84 K |
| Beta | 1.76 | -0.15 |
| Market Capitalization | 1.34 B | 19.03 B |
| Total Asset | 792.34 M | 29.47 B |
| Retained Earnings | (1.56 B) | 9.33 B |
| Working Capital | 707.66 M | 1.48 B |
| Current Asset | 294.94 M | 9.34 B |
| Current Liabilities | 30.24 M | 7.9 B |
| Net Asset | 792.34 M |
Note: Acquisition by Elizabeth Crowley of 85000 shares of Celldex Therapeutics at 36.43 subject to Rule 16b-3 [view details]
Celldex Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Celldex . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 30744.0 | |||
| Daily Balance Of Power | 0.3944 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 20.29 | |||
| Day Typical Price | 20.33 | |||
| Price Action Indicator | 0.28 | |||
| Period Momentum Indicator | 0.28 |
About Celldex Therapeutics Buy or Sell Advice
When is the right time to buy or sell Celldex Therapeutics? Buying financial instruments such as Celldex Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Celldex Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Software Thematic Idea Now
Software
Companies that develop and distribute software and software systems to individuals or business. The Software theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Software Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.